|
US6232297B1
(en)
|
1999-02-01 |
2001-05-15 |
University Of Virginia Patent Foundation |
Methods and compositions for treating inflammatory response
|
|
US7427606B2
(en)
|
1999-02-01 |
2008-09-23 |
University Of Virginia Patent Foundation |
Method to reduce inflammatory response in transplanted tissue
|
|
US7378400B2
(en)
|
1999-02-01 |
2008-05-27 |
University Of Virginia Patent Foundation |
Method to reduce an inflammatory response from arthritis
|
|
US7074801B1
(en)
*
|
2001-04-26 |
2006-07-11 |
Eisai Co., Ltd. |
Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
|
|
EP1434782A2
(en)
|
2001-10-01 |
2004-07-07 |
University of Virginia Patent Foundation |
2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
|
|
US6914053B2
(en)
*
|
2002-09-09 |
2005-07-05 |
Cv Therapeutics, Inc. |
Adenosine A3 receptor agonists
|
|
WO2004086034A2
(en)
*
|
2003-03-28 |
2004-10-07 |
Bayer Healthcare Ag |
Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a3(adora3)
|
|
PL2256106T3
(pl)
|
2003-07-22 |
2015-08-31 |
Astex Therapeutics Ltd |
Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3)
|
|
AR049384A1
(es)
|
2004-05-24 |
2006-07-26 |
Glaxo Group Ltd |
Derivados de purina
|
|
US7442687B2
(en)
|
2004-08-02 |
2008-10-28 |
The University Of Virginia Patent Foundation |
2-polycyclic propynyl adenosine analogs having A2A agonist activity
|
|
US7576069B2
(en)
|
2004-08-02 |
2009-08-18 |
University Of Virginia Patent Foundation |
2-polycyclic propynyl adenosine analogs having A2A agonist activity
|
|
AU2005267706B2
(en)
|
2004-08-02 |
2011-12-08 |
University Of Virginia Patent Foundation |
2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
|
|
AU2005306325A1
(en)
*
|
2004-11-22 |
2006-05-26 |
King Pharmaceuticals Research & Development Inc. |
Enhancing treatment of HIF-1 mediated disorders with adenosine A3 receptor agonists
|
|
MX2007008781A
(es)
|
2005-01-21 |
2007-09-11 |
Astex Therapeutics Ltd |
Compuestos farmaceuticos.
|
|
GB0505219D0
(en)
*
|
2005-03-14 |
2005-04-20 |
Novartis Ag |
Organic compounds
|
|
EP1881991A1
(en)
|
2005-05-19 |
2008-01-30 |
Cv Therapeutics, Inc. |
A1 adenosine receptor agonists
|
|
US7381714B2
(en)
*
|
2005-05-19 |
2008-06-03 |
Cv Therapeutics, Inc. |
A1 adenosine receptor agonists
|
|
GB0514809D0
(en)
|
2005-07-19 |
2005-08-24 |
Glaxo Group Ltd |
Compounds
|
|
WO2007047401A2
(en)
*
|
2005-10-13 |
2007-04-26 |
Cv Therapeutics, Inc. |
A1 adenosine receptor agonists
|
|
WO2007120972A2
(en)
|
2006-02-10 |
2007-10-25 |
University Of Virginia Patent Foundation |
Method to treat sickle cell disease
|
|
US7589076B2
(en)
*
|
2006-05-18 |
2009-09-15 |
Pgx Health, Llc |
Substituted aryl piperidinylalkynyladenosines as A2AR agonists
|
|
US8188063B2
(en)
|
2006-06-19 |
2012-05-29 |
University Of Virginia Patent Foundation |
Use of adenosine A2A modulators to treat spinal cord injury
|
|
DE102007012645A1
(de)
*
|
2007-03-16 |
2008-09-18 |
Bayer Healthcare Ag |
Substituierte Imidazo- und Triazolopyrimidine
|
|
JP2010522719A
(ja)
*
|
2007-03-28 |
2010-07-08 |
ノイロサーチ アクティーゼルスカブ |
プリニル誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用
|
|
EP2132208A1
(en)
|
2007-03-28 |
2009-12-16 |
NeuroSearch AS |
Purinyl derivatives and their use as potassium channel modulators
|
|
US20090088403A1
(en)
*
|
2007-05-07 |
2009-04-02 |
Randy Blakely |
A3 adenosine receptors as targets for the modulation of central serotonergic signaling
|
|
JP2011500716A
(ja)
*
|
2007-10-16 |
2011-01-06 |
ギリアード・パロ・アルト・インコーポレイテッド |
Ａ３アデノシン受容体アンタゴニスト
|
|
US8058259B2
(en)
|
2007-12-20 |
2011-11-15 |
University Of Virginia Patent Foundation |
Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
|
|
RU2451010C1
(ru)
*
|
2011-01-11 |
2012-05-20 |
Закрытое Акционерное Общество "Ива Фарм" |
Палладиево-медные катализаторы гомогенного селективного окисления тиольных групп, комбинация и композиция на их основе и способ терапевтического воздействия
|
|
CA2876780A1
(en)
|
2012-06-26 |
2014-01-03 |
Saniona Aps |
A phenyl triazole derivative and its use for modulating the gabaa receptor complex
|
|
WO2014138485A1
(en)
*
|
2013-03-08 |
2014-09-12 |
Irm Llc |
Ex vivo production of platelets from hematopoietic stem cells and the product thereof
|
|
AU2018269403B2
(en)
*
|
2017-05-19 |
2025-03-27 |
Alltech, Inc. |
Pharmaceutical agents, compositions, and methods relating thereto
|
|
WO2020185859A1
(en)
|
2019-03-12 |
2020-09-17 |
Arcus Biosciences, Inc. |
Treatment of oncogene-driven cancers
|
|
US12310965B2
(en)
|
2019-03-29 |
2025-05-27 |
Arcus Biosciences, Inc. |
Treatment of cancer utilizing an identified adenosine fingerprint
|
|
EP3988100A4
(en)
*
|
2019-06-21 |
2023-07-26 |
Academy of Military Medical Sciences |
ADENOSINE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT OR STEREOISOMERIDE THEREOF AND USE
|
|
WO2022143740A1
(zh)
*
|
2020-12-29 |
2022-07-07 |
浙江春禾医药科技有限公司 |
A3腺苷受体激动剂及其制备方法和用途
|